Abstract 5769
Background
Information about chemotherapy is complex. Access to information prior to treatment enables patients to gain a better understanding of their condition, lessen their concerns and enables them to make informed choices about treatment. Traditionally chemotherapy education was provided by oncology clinical nurse specialists (CNS) on an individual basis to patients before they started chemotherapy. Increasing numbers of patients and reduced staff resources lead to problems maintaining service. The Irish Cancer Society’s Daffodil Centres are committed to quality improvement across cancer services available to those affected by cancer. Mater Misericordiae University Hospital (MMUH) and the Irish Cancer Society’s Daffodil Centre collaborated on a group chemotherapy initiative in 2012 initiated in response to a high demand for education services. After a successful pilot the programme is now running in 8 hospitals across Ireland. In 2018 342 group education sessions were held with 1713 attendees.
Methods
The Cancer Nurse in the Daffodil Centre facilitates this programme using educational tools including a specially produced audiovisual support (DVD) and short oral and practical demonstrations to assist different learning styles. To conclude the CNS meets with the patients to discuss their individual plan. All attendees are asked to complete an evaluation form which is inputted into a database and the results collated.
Results
1217 completed the evaluation out of 1713 attendees. A number of themes emerged including: • Welcoming • Good information • Allayed concerns • Empowerment. Acknowledgement of the expertise of the nurse and other allied healthcare professionals who present at the session – medical social workers and dietitians.
Conclusions
Overall satisfaction levels were very high in the programme including the information and content on the DVD and the information received and the way it was explained by the nurse. Of those who left comments they were very positive about the experience and for the opportunity to attend. By attending the session patients and their relative/friends were made to feel welcome. Their knowledge of chemotherapy and its side effects were greatly increased and their fears of commencing treatment were in many ways alleviated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract